Pedro Granadillo
Direttore/Membro del Consiglio presso ROCKET PHARMACEUTICALS, INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Pedro P.
Granadillo is the founder of Neumentum, Inc. (2017).
He is also the founder of Umbria Pharmaceuticals, LLC.
Pedro's current job is as an Independent Director at Rocket Pharmaceuticals, Inc. (2018 - present).
Mr. Granadillo's former jobs include Chairman at Kirax Corp.
(2009 - 2010), Chairman at Aura Biosciences, Inc., Director at First Indiana Corp.
(2002 - 2008), Director at Noven Pharmaceuticals, Inc. (2004 - 2009), Independent Director at NPS Pharmaceuticals, Inc. (2010 - 2015), Independent Director at Haemonetics Corp.
(2004 - 2019), Independent Director at Dendreon Corp.
(2009 - 2014), Director at First Indiana Bank, NA (2002 - 2007), Independent Director at Capricor Therapeutics, Inc. (2007 - 2013), Director at Health Sciences Acquisitions Corp., and Independent Director at Health Sciences Acquisitions Corp.
2.
Mr. Granadillo's education history includes an undergraduate degree from Purdue University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 13/06/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Pedro Granadillo
| Società | Posizione | Inizio |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 04/01/2018 |
| Umbria Pharmaceuticals, LLC | Fondatore | - |
Precedenti posizioni note di Pedro Granadillo
| Società | Posizione | Fine |
|---|---|---|
| HAEMONETICS CORPORATION | Direttore/Membro del Consiglio | 25/07/2019 |
| NPS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 01/01/2015 |
| DENDREON CORPORATION | Direttore/Membro del Consiglio | 04/03/2014 |
| CAPRICOR THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 20/11/2013 |
Noven Pharmaceuticals, Inc.
 Noven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Noven Pharmaceuticals, Inc. operates as a pharmaceutical company with transdermal expertise. It specializes in the research and development, manufacture, marketing, and sale of prescription pharmaceutical products. The company was founded in 1987 and is headquartered in Miami, FL. | Direttore/Membro del Consiglio | 01/01/2009 |
Formazione di Pedro Granadillo
| Purdue University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| HAEMONETICS CORPORATION | Health Technology |
| CAPRICOR THERAPEUTICS, INC. | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 10 |
|---|---|
First Indiana Corp.
 First Indiana Corp. Major BanksFinance First Indiana Corp. provides financial services. It operates as a holding company for First Indiana Bank which takes deposits from the public and originates residential mortgage, business, and commercial loans. The company is headquartered in Indianapolis city, IN. | Finance |
Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Noven Pharmaceuticals, Inc. operates as a pharmaceutical company with transdermal expertise. It specializes in the research and development, manufacture, marketing, and sale of prescription pharmaceutical products. The company was founded in 1987 and is headquartered in Miami, FL. | Health Technology |
| First Indiana Bank, NA | Finance |
Kirax Corp.
 Kirax Corp. Pharmaceuticals: MajorHealth Technology Kirax Corp. researches, develops, manufactures and distributes pharmaceutical products. The firm provides specialty care therapies to treat oncology, pain, inflammation, acute, and supportive care areas of unmet medical need. The company was founded by Mark E. Pruzanski, David M. Tanen and Edmundo Muniz in 2005 and is headquartered in Bonita Springs, FL. | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
| Umbria Pharmaceuticals, LLC | |
Neumentum, Inc.
 Neumentum, Inc. Pharmaceuticals: MajorHealth Technology Neumentum, Inc. engages in the provision of pharmaceutical services. It specializes in non-opioid analgesic and neurology specialty where patient with acute and chronic pain. The company was founded by R. Scott Shively and Joseph V. Pergolizzi, Jr. on April 6, 2017 and is headquartered in Palo Alto, CA. | Health Technology |
Health Sciences Acquisitions Corp.
 Health Sciences Acquisitions Corp. Financial ConglomeratesFinance Health Sciences Acquisitions Corp. operates as a blank check company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It pursues prospective targets that are focused on healthcare innovation domiciled in North America or Europe that are developing assets in the biopharma and medical technology sectors. The company was founded on December 06, 2018 and is headquartered in New York, NY. | Finance |
Health Sciences Acquisitions Corp. 2
 Health Sciences Acquisitions Corp. 2 Financial ConglomeratesFinance Health Sciences Acquisitions Corp. 2 is a blank check company, which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on May 25, 2020 and is headquartered in New York, NY. | Finance |
- Borsa valori
- Insiders
- Pedro Granadillo
